Bhaskar Kusuma

Bhaskar Kusuma joined NJ Bio, Inc. as Principal Scientist in Analytical Development and is currently Vice President, Analytical R&D. Bhaskar has over 10 years of extensive experience in the field of analytical method development, method optimization, and phase-appropriate method validation for the characterization of small molecules, peptides, proteins, oligonucleotides, antibodies, and Antibody Drug Conjugates (ADCs). Before joining NJ Bio, Bhaskar worked in the Analytical Method Development group at SciGen Pharmaceuticals, Amneal Pharmaceuticals, and Ajinomoto Biopharmaceuticals. He obtained his Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology on the development of novel synthetic methodologies and formal synthetic methodologies and formal total synthesis of bafilomycin A1. After his Ph.D., Bhaskar was a post-doctoral fellow at the University of British Columbia & University of Kansas in medicinal chemistry. At Kansas University, he worked on the design, synthesis, and biological evaluation of HSP90 inhibitors to target multiple cancer, and developed a novel HSP90 c-terminal inhibitor as a potential candidate for treating Alzheimer’s and Parkinson's disease; currently, this molecule is in Phase 2 clinical.